Eiger raises $49.5M following Phase II HDV readout for Lambda

Eiger reported data from the Phase II LIMT HDV trial showing that high-dose Lambda as monotherapy led to a 36% durable virologic response rate at 24 weeks following treatment among 14 evaluable patients with chronic hepatitis D virus infection. The company said it will discuss the data with regulatory authorities.

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) reported the data at the European Association for the Study of the Liver (EASL) meeting in Vienna on April 11, and then raised $49.5 million on April 17 through the sale of 4.5 million shares at $11 in a follow-on underwritten by Citigroup, Jefferies, BTIG, Ladenburg Thalmann and Baird...